Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/153788
Author(s): Fernandes, G
Sousa, C
Reis, J
Martins, N
Moura, CS
Guimarães, S
Justino, A
Pina, MJ
Magalhães, A
Queiroga, H
Marques, JA
Machado, JC
Costa, JL
Hespanhol, V
Title: Liquid biopsy for disease monitoring in non-small cell lung cancer: The link between biology and the clinic
Publisher: MDPI
Issue Date: 2021
Abstract: Introduction: Cell-free DNA (cfDNA) analysis offers a non-invasive method to identify sensitising and resistance mutations in advanced Non-Small Cell Lung Cancer (NSCLC) patients. Next-generation sequencing (NGS) of circulating free DNA (cfDNA) is a valuable tool for mutations detection and disease' s clonal monitoring. Material and methods: An amplicon-based targeted gene NGS panel was used to analyse 101 plasma samples of advanced non-small cell lung cancer (NSCLC) patients with known oncogenic mutations, mostly EGFR mutations, serially collected at different clinically relevant time points of the disease. Results: The variant allelic frequency (VAF) monitoring in consecutive plasma samples demonstrated different molecular response and progression patterns. The decrease in or the clearance of the mutant alleles was associated with response and the increase in or the emergence of novel alterations with progression. At the best response, the median VAF was 0% (0.0% to 3.62%), lower than that at baseline, with a median of 0.53% (0.0% to 9.9%) (p = 0.004). At progression, the VAF was significantly higher (median 4.67; range: 0.0–36.9%) than that observed at the best response (p = 0.001) and baseline (p = 0.006). These variations anticipated radiographic changes in most cases, with a median time of 0.86 months. Overall, the VAF evolution of different oncogenic mutations predicts clinical outcomes. Conclusion: The targeted NGS of circulating tumour DNA (ctDNA) has clinical utility to monitor treatment response in patients with advanced lung adenocarcinoma.
Subject: Adenocarcinoma
Cell-free DNA
Clinical outcomes
Liquid biopsy
Lung cancer
Next-generation sequencing
Tumour-free DNA
URI: https://hdl.handle.net/10216/153788
Source: Cells, vol.10(8):1912
Document Type: Artigo em Revista Científica Internacional
Rights: openAccess
License: https://creativecommons.org/licenses/by/4.0/
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-cells10081912.pdf3.01 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons